RECRUITING

Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Description

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Conditions

Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small CellCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, NeuroendocrineCarcinoma, ThymicCarcinoma, PancreaticCarcinoma BreastCarcinoma, OvarianCarcinoma BladderCarcinoma of Unknown PrimaryCarcinoma of the Head and NeckCarcinoma of the OropharynxCarcinoma of the LarynxCarcinoma of the BladderCarcinoma of EsophagusCarcinoma of the NasopharynxCarcinoma of the PenisCarcinoma of the CervixCarcinoma of the AnusCarcinoma of the VulvaCarcinoma of the AppendixCarcinoma of the Oral CavityCholangiocarcinomaMelanomaMesotheliomaPancreatic Cancer
Talk to us

Related Conditions:

Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small CellCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, NeuroendocrineCarcinoma, ThymicCarcinoma, PancreaticCarcinoma BreastCarcinoma, OvarianCarcinoma BladderCarcinoma of Unknown PrimaryCarcinoma of the Head and NeckCarcinoma of the OropharynxCarcinoma of the LarynxCarcinoma of the BladderCarcinoma of EsophagusCarcinoma of the NasopharynxCarcinoma of the PenisCarcinoma of the CervixCarcinoma of the AnusCarcinoma of the VulvaCarcinoma of the AppendixCarcinoma of the Oral CavityCholangiocarcinomaMelanomaMesotheliomaPancreatic Cancer

Study Overview

On this page

Study Details

Study overview

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance

Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Condition
Pleural Effusion, Malignant
Intervention / Treatment

-

Contacts and Locations

Oakland

xCures, Oakland, California, United States, 94612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patient is ≥18 years of age
  • 2. Written Informed Consent provided by patient
  • 3. Diagnosis of any kind of carcinoma
  • 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
  • 5. Proceeding onto therapy for treatment
  • 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)
  • 1. Lack of informed consent
  • 2. Unable to obtain sufficient sample

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Travera Inc,

Mark Stevens, Phd, PRINCIPAL_INVESTIGATOR, Travera Inc

Rob Kimmerling, Phd, PRINCIPAL_INVESTIGATOR, Travera Inc

Study Record Dates

2026-07